Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quotient Sciences Invests £6.3M in Drug Substance Mfg. Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Quotient Sciences Invests £6.3M in Drug Substance Mfg. Facility

To significantly expand drug substance manufacturing capability at Alnwick, UK facility and create 80 new jobs over the next three years.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Quotient Sciences is investing £6.3 million in its recently acquired manufacturing facility in Alnwick, UK, to significantly expand its drug substance manufacturing capability and create 80 new jobs over the next three years.
 
Quotient acquired the Alnwick facility from Arcinova in February 2021 to expand its services to include drug substance, drug product and clinical testing capabilities under one organization. The acquisition enables Quotient to support customers from candidate selection through commercial product launch. The investment will repurpose a 1,500 square-meter footprint and incorporate additional equipment and technologies, significantly expanding the number of new molecules developed each year.
 
Additional equipment, featuring advanced digital control and data capture, will support robust transfer from lab to multi-kilo scale production. Processing equipment with new developments in modular continuous technology will help maximize responsiveness and agility for manufacturing processes. The five-fold increase in scale will increase Quotient’s capacity by over 10 times for developing complex medicines.
 
“Following our integration into Quotient Sciences earlier in the year, it is tremendously exciting to see the Alnwick facility continue to expand capabilities as we move into larger scale and commercial manufacturing,” said Quotient Sciences SVP Candidate Development Services Roger Kilburn. “Science and agility are at the core of Quotient Sciences, and our team strives to innovate and develop smarter approaches to process R&D for our customers and drive the adoption of continuous processing technologies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics